BACKGROUND: U19/EAF2 is a potential tumor suppressor exhibiting frequent down-regulation and allelic loss in advanced human prostate cancer specimens. U19/EAF2 has also been identified as ELL-associated factor 2 (EAF2) based on its binding to ELL, a fusion partner of MLL in acute myeloid leukemia. U19/EAF2 is a putative transcription factor with a transactivation domain and capability of sequence-specific DNA binding. METHODS: Yeast-two-hybrid-screening was used to identify U19/EAF2-binding partners. Co-immunoprecipitation and mammalian 1-hybrid assay were used to characterize a U19/EAF2-binding partner. RESULTS: FB1, an E2A fusion partner in childhood leukemia, was identified as a binding-partner of U19/EAF2. FB1 also binds to EAF1, the only homologue of U19/EAF2. FB1 also interacts and co-localizes with ELL in the nucleus. Interestingly, FB1 inhibited the transcriptional activity of U19/EAF2 but not EAF1. CONCLUSIONS: FB1 is an important binding partner and a functional regulator of U19/EAF2, EAF1, and/or ELL.
BACKGROUND:U19/EAF2 is a potential tumor suppressor exhibiting frequent down-regulation and allelic loss in advanced humanprostate cancer specimens. U19/EAF2 has also been identified as ELL-associated factor 2 (EAF2) based on its binding to ELL, a fusion partner of MLL in acute myeloid leukemia. U19/EAF2 is a putative transcription factor with a transactivation domain and capability of sequence-specific DNA binding. METHODS: Yeast-two-hybrid-screening was used to identify U19/EAF2-binding partners. Co-immunoprecipitation and mammalian 1-hybrid assay were used to characterize a U19/EAF2-binding partner. RESULTS:FB1, an E2A fusion partner in childhood leukemia, was identified as a binding-partner of U19/EAF2. FB1 also binds to EAF1, the only homologue of U19/EAF2. FB1 also interacts and co-localizes with ELL in the nucleus. Interestingly, FB1 inhibited the transcriptional activity of U19/EAF2 but not EAF1. CONCLUSIONS:FB1 is an important binding partner and a functional regulator of U19/EAF2, EAF1, and/or ELL.
Authors: F Brambillasca; G Mosna; M Colombo; A Rivolta; C Caslini; M Minuzzo; G Giudici; L Mizzi; A Biondi; E Privitera Journal: Leukemia Date: 1999-03 Impact factor: 11.528
Authors: K Mitani; T Yamagata; C Iida; H Oda; K Maki; M Ichikawa; T Asai; H Honda; M Kurokawa; H Hirai Journal: Biochem Biophys Res Commun Date: 2000-12-20 Impact factor: 3.575